Les avantages thérapeutiques d'un topique bio-adhésif à base de VBM dans le traitement du psoriasis en plaques. Présentation des résultats d'une nouvelle étude européenne, multicentrique

Topical treatments remain the gold standard for treating stable plaque psoriasis with little or moderate extension. Dermocorticoids alone or in association with other drugs are the most frequently used medications in these situations and account for approximately 85% of the prescriptions in daily practice. Despite the efficacy of topical corticoid therapy, patients report they are dissatisfied with current treatments. The use of these treatments under occlusion reinforces their effectiveness, but the quantities applied are highly variable and the plastic films are sometimes difficult to maintain in place or are incompatible with social life. The arrival on the market of a dermocorticoid as a bioadhesive plaster (Betesil®) is the opportunity to rigorously evaluate the efficacy of occlusion as well as patient tolerance and acceptance. The results show that Betesil® is an effective innovating therapeutic solution and is well tolerated and accepted by patients.